FDA Warning: Second Cancers Can Follow Lenalidomide in Myeloma

The Food and Drug Administration has added a warning about second-cancer risk to the label of lenalidomide, a widely used multiple myeloma drug, after a safety review lasting about 1 year.Treatment with... (Source: OncologySTAT Latest News)

Source: http://www.medworm.com/index.php?rid=6032269&cid=u_0_6_f&fid=38623&url=http%3A%2F%2Fwww.oncologystat.com%3A80%2Fnews%2FFDA_Warning__Second_Cancers_Can_Follow_Lenalidomide_in_Myeloma__US.html

phlebotomy training in riverside ca phlebotomy training course information get phlebotomy certification